However, now that 2021 has begun, the one-year decline will age out when AbbVie reports full-year 2020 results, which are forecast to be $19.1 billion. This year's total should be even higher. Even with the slightly lower free cash flow total in 2019, AbbVie had more than enough to afford the $6.4 billion in dividends that it paid. That figure is expected to have grown to $8.4 billion in 2020, which is just 44% of projected free cash flow. (Anything below 50% is considered quite safe.) AbbVie was spun out of Abbott Laboratories (NYSE: ABT) in 2013. It has paid and raised its dividend every year since, so its dividend-paying history is short but solid. AbbVie should have absolutely no problem paying and raising its dividend in 2021. And I expect it will be upgraded to SafetyNet Pro's highest rating in a few weeks once the 2020 results are in. Dividend Safety Rating: B If you have a stock whose dividend safety you'd like me to analyze, leave the ticker in the comments section. You can also search the Wealthy Retirement website to see whether I've written about your favorite stock before. Simply type its name into the search bar below. Good investing, Marc P.S. A 2,381% partial options gain is pretty remarkable - but I'm planning to beat that record in 2021. This time, I want to show my subscribers the chance at 3,000% in a year. But here's the catch - this is the only way you can get in at this offer. So you have to act fast. Click here for the details. | 
No comments:
Post a Comment